Tafenoquine Thorough QTc Study in Healthy Subjects
Status:
Completed
Trial end date:
2012-06-04
Target enrollment:
Participant gender:
Summary
This will be a randomized, single-blind, placebo controlled, parallel group study.
Approximately 260 subjects will be enrolled in five groups. This study is designed to compare
the effects of tafenoquine, administered as single dose as well as administered over three
consecutive days, on the changes in QT duration to those observed in subjects dosed with
either moxifloxacin or placebo.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination Tafenoquine